Fund Holdings — Versant Venture Management, LLC

Total Portfolio Value
$212.45M
Total Bought
$123.76M
Total Sold
$14.60M
Net Transaction
+$109.15M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Lenz Therapeutics, Inc.(LENZ)02,656,888+2,656,8880123,75858.25%+123,758
Monte Rosa Therapeutics, Inc.(GLUE)5,652,9225,652,922025,49541,88819.72%+16,393
Contineum Therapeutics, Inc.(CTNM)542,628542,62802,1546,3763.00%+4,222
Adverum Biotechnologies, Inc.506,821506,82101,0902,2961.08%+1,206
Repare Therapeutics, Inc.2,646,6572,646,65703,6794,6582.19%+979
Tempest Therapeutics, Inc.(TPST)269,772269,77201,8342,7731.31%+939
Skye Bioscience, Inc.(SKYE)2,007,7042,007,70408,3927,8903.71%-502
Jade Biosciences, Inc.1,525,8201,525,820015,24313,1686.20%-2,075
CRISPR Therapeutics AG(CRSP)498,558148,831-349,72724,2509,6464.54%-14,604
Page 1 of 1
Versant Venture Management, LLC — 13F Holdings — Q3 2025 | TickerTrail